Corinne Haïoun

1986–2025 年に発表

170
論文数
32,015
被引用数
103
h 指数
165
i10 指数

被引用数

Corinne Haïoun の年別被引用数1988 年: 被引用 2 件1989 年: 被引用 4 件1990 年: 被引用 6 件1991 年: 被引用 2 件1993 年: 被引用 6 件1994 年: 被引用 5 件1995 年: 被引用 10 件1996 年: 被引用 15 件1997 年: 被引用 50 件1998 年: 被引用 47 件1999 年: 被引用 35 件2000 年: 被引用 75 件2001 年: 被引用 86 件2002 年: 被引用 84 件2003 年: 被引用 105 件2004 年: 被引用 88 件2005 年: 被引用 127 件2006 年: 被引用 119 件2007 年: 被引用 131 件2008 年: 被引用 134 件2009 年: 被引用 132 件2010 年: 被引用 146 件2011 年: 被引用 217 件2012 年: 被引用 192 件2013 年: 被引用 171 件2014 年: 被引用 229 件2015 年: 被引用 221 件2016 年: 被引用 218 件2017 年: 被引用 277 件2018 年: 被引用 236 件2019 年: 被引用 863 件2020 年: 被引用 942 件2021 年: 被引用 910 件2022 年: 被引用 697 件2023 年: 被引用 454 件2024 年: 被引用 743 件2025 年: 被引用 353 件2026 年: 被引用 5 件1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,161 件、この内訳の 22.6%フランス: 引用元論文 868 件、この内訳の 9.1%ドイツ: 引用元論文 688 件、この内訳の 7.2%イタリア: 引用元論文 620 件、この内訳の 6.5%中国: 引用元論文 589 件、この内訳の 6.2%イギリス: 引用元論文 583 件、この内訳の 6.1%カナダ: 引用元論文 371 件、この内訳の 3.9%スペイン: 引用元論文 364 件、この内訳の 3.8%スイス: 引用元論文 342 件、この内訳の 3.6%日本: 引用元論文 307 件、この内訳の 3.2%オランダ: 引用元論文 295 件、この内訳の 3.1%オーストラリア: 引用元論文 249 件、この内訳の 2.6%
0%22.6%その他 22.1%

分野

  • Medicine84.8%
  • Biochemistry, Genetics and Molecular Biology9.1%
  • Immunology and Microbiology5.1%
  • Computer Science0.3%
  • Neuroscience0.2%
  • Mathematics0.1%
  • その他0.4%

トピック

  • Lymphoma Diagnosis and Treatment22.4%
  • CAR-T cell therapy research6.3%
  • CNS Lymphoma Diagnosis and Treatment5.9%
  • Chronic Lymphocytic Leukemia Research5.8%
  • Viral-associated cancers and disorders5.5%
  • Cutaneous lymphoproliferative disorders research3.9%
  • その他50.2%

共著者

全論文

検索で開く
  1. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

    著者: , , , , , , , , , , , , , - Blood 2020 被引用: 378

  2. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski ほか 69 名 - The Lancet 2018 被引用: 726

  3. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 被引用: 410

  4. Management and outcome of primary CNS lymphoma in the modern era

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Corinne Haïoun, Safia Chebrek, Anna Schmitt, Marie Blonski, Roch Houot, Eileen M. Boyle, Jacques‐Olivier Bay, Lucie Obéric, Émeline Tabouret, Agathe Waultier, N. Martin–Duverneuil, Valérie Touitou, Nathalie Cassoux, Aurélie Kas, Karima Mokhtari, Frédéric Charlotte, Agustí Alentorn, L. Feuvret, Magali Le Garff‐Tavernier, Myrto Costopoulos, Bertrand Mathon, Matthieu Peyre, Daniel Delgadillo, Hassen Douzane, Diane Genet, Bachir Aidaoui, Khê Hoang‐Xuan, Emmanuel Gyan - Neurology 2020 被引用: 245

  5. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2023 被引用: 77

  6. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 643

  7. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Liu, Jianming Wang, Luc Xerri, Gilles Salles - New England Journal of Medicine 2018 被引用: 362

  8. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Masao Seto, Andreas Rosenwald, German Ott, Elı́as Campo, Lisa M. Rimsza, Elaine S. Jaffe, Rita M. Braziel, Francesco d’Amore, Giorgio Inghirami, Francesco Bertoni, Laurence de Leval, Philippe Gaulard, Louis M. Staudt, Timothy W. McKeithan, Stefano Pileri, Wing C. Chan, Javeed Iqbal - Blood 2019 被引用: 275

  9. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

    著者: , , , , , , , , , - Journal of Clinical Oncology 1997 被引用: 641

  10. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan Fowler, Gilles Salles - Journal of Clinical Oncology 2022 被引用: 68

  11. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2011 被引用: 545

  12. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 被引用: 220

  13. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

    著者: , , , , , , , , , , , , , , , - Haematologica 2013 被引用: 171

  14. Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 337

  15. Report on the First International Workshop on interim-PET scan in lymphoma

    著者: , , , , - Leukemia & lymphoma/Leukemia and lymphoma 2009 被引用: 751

  16. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin

    著者: , , , , , , , , , , , , , , , , , , , , - Haematologica 2017 被引用: 224

  17. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma

    著者: , , , , , , , , , , , , , - Blood 2018 被引用: 178

  18. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2010 被引用: 1,066

  19. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 412

  20. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 被引用: 318

  21. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2013 被引用: 303

  22. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Françoise Berger, Céline Bossard, Flavie Arbion, Isabelle Quintin‐Roué, Jean‐Michel Picquenot, Martine Patey, Blandine Fabre, Henri Sevestre, Cécile Le Naourès, Marie-Pierre Chenard-Neu, Claire Bastien, S. Thiebault, Laurent Martin, Manuela Delage, Thomas Filleron, Gilles Salles, Thierry Jo Molina, Georges Delsol, Pierre Brousset, Philippe Gaulard - Journal of Clinical Oncology 2017 被引用: 217

  23. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 195

  24. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2011 被引用: 357